Free Trial

Seer, Inc. (NASDAQ:SEER) Sees Large Decrease in Short Interest

Seer logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Short interest in Seer fell sharply by 40.9% in April to 432,590 shares (about 0.9% of float), leaving a short-interest ratio of roughly 0.9 days.
  • Institutional ownership is high at 75.20%, with several firms opening positions and Barclays boosting its stake by 685% to 60,717 shares.
  • Seer has a market cap of about $111.2M; it reported a $0.29 loss per share that beat estimates but missed on revenue ($4.20M vs. $4.60M), and analyst views are mixed (one Strong Buy, one Sell; average "Moderate Buy").
  • Five stocks we like better than Seer.

Seer, Inc. (NASDAQ:SEER - Get Free Report) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 432,590 shares, a drop of 40.9% from the March 31st total of 732,581 shares. Based on an average daily trading volume, of 506,721 shares, the short-interest ratio is currently 0.9 days. Approximately 0.9% of the shares of the company are short sold.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Occudo Quantitative Strategies LP acquired a new position in shares of Seer in the 2nd quarter worth approximately $25,000. Marshall Wace LLP acquired a new position in shares of Seer in the 4th quarter worth approximately $85,000. Quadrature Capital Ltd acquired a new position in shares of Seer in the 4th quarter worth approximately $101,000. Barclays PLC boosted its holdings in shares of Seer by 685.0% in the 4th quarter. Barclays PLC now owns 60,717 shares of the company's stock worth $111,000 after acquiring an additional 52,982 shares in the last quarter. Finally, Corient Private Wealth LLC acquired a new position in shares of Seer in the 4th quarter worth approximately $116,000. Institutional investors own 75.20% of the company's stock.

Seer Price Performance

NASDAQ:SEER opened at $1.97 on Monday. Seer has a 12-month low of $1.65 and a 12-month high of $2.41. The firm has a market capitalization of $111.15 million, a PE ratio of -1.54 and a beta of 1.59. The firm has a 50-day moving average price of $1.84 and a 200 day moving average price of $1.92.

Seer (NASDAQ:SEER - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.03. Seer had a negative net margin of 443.96% and a negative return on equity of 26.04%. The firm had revenue of $4.20 million during the quarter, compared to analyst estimates of $4.60 million.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on SEER shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Seer in a research note on Tuesday, April 21st. TD Cowen upgraded shares of Seer to a "strong-buy" rating in a research note on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Seer presently has an average rating of "Moderate Buy".

Get Our Latest Stock Analysis on Seer

Seer Company Profile

(Get Free Report)

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer's platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company's flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Seer Right Now?

Before you consider Seer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seer wasn't on the list.

While Seer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines